Karen S. Jacks, MD is part of Comprehensive Cancer’s board certified and award-winning medical oncologist team that provides world-class cancer care in a supportive and caring environment.
Karen S. Jacks, MD, completed her undergraduate studies at the University of North Carolina at Chapel Hill and earned her medical degree at Brody School of Medicine at East Carolina University. She completed her internal medicine residency at the University Health Systems of Eastern Carolina, Pitt County Memorial Hospital, where she served as Chief Medical Resident and Clinical Assistant Professor. She completed her hematology/medical oncology fellowship at University Health Systems of Eastern Carolina, Pitt County Memorial Hospital and Leo Jenkins Cancer Center.
Dr. Jacks is a medical oncologist-hematologist at Comprehensive Cancer Centers of Nevada (CCCN). Prior to joining CCCN, Dr. Jacks worked at UC San Diego Nevada Cancer Institute and Nevada Cancer Institute (NVCI), where she focused on breast cancer and other female cancers and served as Assistant Professor for Medical Oncology. Dr. Jacks also served as Co-Chair for the Cancer Control Committee and member of the Blood Utilization Committee. She previously served as an oncology fellowship preceptor, Medical Director of Oncology Services at University Medical Center, and as the oncology rotation residency coordinator at the University of Nevada School of Medicine.
Dr. Jacks has published numerous peer-reviewed publications and presentations. She received the Eugene Furth, MD Award for Most Outstanding Senior Resident, and the Sir Williams Osler Award for Best Senior Resident in Cardiology. She has also been recognized as a Medical Marvel by Nevada Business Magazine.
Dr. Jacks is a native of North Carolina. In her spare time, she enjoys spending time with her family and sewing.
I care for each patient as a special individual as I would treat members of my own family.
Alpha Omega Alpha
American Society of Clinical Oncology
American Medical Association
Clark County Medical Society
AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. Read more.